Recovery From Schizophrenia: Psychiatry And Political Economy

NOTES 355Archives of General Psychiatry, 36:1283–94, 1979; Goldstein et al., “Drug and familytherapy.”58 Voruganti, L.N.P., Heslegrave, R.J. and Awad, A,G., “Neuroleptic dysphoria maybe the missing link between schizophrenia and substance abuse,” Journal of Nervousand Mental Disease, 185:463–5, 1997; Warner, R., Taylor, D., Wright, J. et al.,“Substance use among the mentally ill: Prevalence, reasons for use and effects onillness,” American Journal of Orthopsychiatry, 64:465–76, 1994.59 Hartlage, L.C., “Effects of chlorpromazine on learning,” Psychological Bulletin, 64:235–45, 1965; Bruening, S.E., Davis, V.J., Matson, J.L. and Ferguson, D.G,“Effects of thioridazine and withdrawal dyskinesias on workshop performance ofmentally retarded young adults,” American Journal of Psychiatry, 139:1447–54, 1982.60 Henderson, D.C., Cagliero, E., Gray, C. et al., “Clozapine, diabetes mellitus, weightgain, and lipid abnormalities: A five-year naturalistic study,” American Journal ofPsychiatry, 157:975–81, 2000.61 Blackburn, G.L., “Weight gain and antipsychotic medication,” Journal of ClinicalPsychiatry, 61 (supplement 8): 36–41, 2000.62 Physicians’ Desk Reference, 47th Edition, Montvale, New Jersey: Medical EconomicsData, 1993, pp. 2093–7; Henderson, “Clozapine, diabetes mellitus, weight gain, andlipid abnormalities.”63 Chakos, M., Lieberman, J., Hoffman, E. et al., “Effectiveness of secondgenerationantipsychotics in treatment-resistant schizophrenia: A review and meta-analysis ofrandomized trials,” American Journal of Psychiatry, 158:518–26, 2001; Geddes, J.,Freemantle, N., Harrison, P. and Bebbington, P. “Atypical antipsychotics in thetreatment of schizophrenia: Systematic overview and meta regression analysis,”British Medical Journal, 321:1371–2000, 2000.64 Newcomer, J.W., Haupt, D.W., Fucetola, R. et al., “Abnormalities in glucoseregulation during antipsychotic treatment of schizophrenia,” Archives of GeneralPsychiatry, 59:337–45, 2002.65 Commonwealth of Massachusetts Executive Office of Health and Human ServicesDepartment of Mental Health, Mortality Report 1998–1999, Boston, Massachusetts,2001.66 Department of Mental Health Central Massachusetts Area Office, Morbidity Study:Medical Illnesses of Central Massachusetts Area DMH Residential Clients, Worcester,Massachusetts, 2001.67 Bradley, K., Nguyen, M. and Pelletier, J.R., “Genesis Wellness Project,” presentedat the second meeting of the Research Advisory Committee for the Program forClubhouse Research, University of Massachusetts Medical School, Worcester,Massachusetts, June 22, 2002.68 Taylor, D.P., Riblet, L.A., Stanton, H.C. et al., “Dopamine and anti-anxietyactivity,” Pharmacology, Biochemistry and Behavior, vol. 17, supplement 1, pp. 25–35,1982; Haefely, W.E., “Behavioral and neuropharmacological aspects of drugs usedin anxiety and related states,” in M.A. Lipton, A.DiMascio and K.F.Killam (eds),Psychopharmacology: A Generation of Progress, New York: Raven Press, 1978;Nestoros, J.N., “Benzodiazepines in schizophrenia: A need for a reassessment,”International Pharmacopsychiatry, 15:171–9, 1980; Bunney, G.S. and Aghajanian,G.K., “The effect of antipsychotic drugs on the firing of dopaminergic neurons: Areappraisal,” in G.Sedvall, G.Uvnäs and Y.Zotterman, Antipsychotic Drugs:Pharmacodynamics and Pharmacokinetics, New York: Pergamon, 1976.